2021 Q4 Form 10-Q Financial Statement

#000095017021003917 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.284M $5.487M $4.320M
YoY Change 22.31% 38.91% 49.48%
% of Gross Profit
Research & Development $9.214M $14.81M $14.62M
YoY Change -36.98% 22.09% 10.09%
% of Gross Profit
Depreciation & Amortization $464.0K $106.0K $100.0K
YoY Change 364.0% 17.78% 25.0%
% of Gross Profit
Operating Expenses $14.50M $14.81M $18.94M
YoY Change -23.45% 22.09% 17.13%
Operating Profit -$20.30M
YoY Change 26.26%
Interest Expense -$2.309M $2.327M -$1.140M
YoY Change 102.54% 88.42% 123.53%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$16.81M -$22.63M -$20.08M
YoY Change -16.3% 32.47% 20.38%
Income Tax -$20.00K
% Of Pretax Income
Net Earnings -$16.81M -$22.63M -$20.07M
YoY Change -16.26% 32.49% 20.4%
Net Earnings / Revenue
Basic Earnings Per Share -$0.86
Diluted Earnings Per Share -$635.4K -$860.1K -$804.1K
COMMON SHARES
Basic Shares Outstanding 26.44M 26.30M
Diluted Shares Outstanding 26.30M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $71.22M $88.71M $72.80M
YoY Change -2.17% -0.55% -35.17%
Cash & Equivalents $19.86M $17.63M $15.87M
Short-Term Investments $51.36M $71.07M $56.90M
Other Short-Term Assets $6.175M $3.983M $5.200M
YoY Change 18.75% 24.47% -1.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $77.39M $92.69M $77.93M
YoY Change -0.69% 0.42% -33.72%
LONG-TERM ASSETS
Property, Plant & Equipment $527.0K $938.0K $1.023M
YoY Change -48.48% -12.58% 9.53%
Goodwill $881.0K $881.0K $881.0K
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.957M $1.626M $1.477M
YoY Change 32.5% 70.08% 60.89%
Total Long-Term Assets $5.919M $6.077M $6.169M
YoY Change -4.05% 5.3% 6.25%
TOTAL ASSETS
Total Short-Term Assets $77.39M $92.69M $77.93M
Total Long-Term Assets $5.919M $6.077M $6.169M
Total Assets $83.31M $98.77M $84.10M
YoY Change -0.94% 0.7% -31.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.044M $7.181M $5.146M
YoY Change -1.98% 78.94% 30.44%
Accrued Expenses $7.633M $8.272M $8.584M
YoY Change -11.08% 32.56% 57.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.94M $15.72M $13.97M
YoY Change -7.4% 49.75% 44.09%
LONG-TERM LIABILITIES
Long-Term Debt $128.1M $125.8M $63.40M
YoY Change 101.99% 102.5% 46.42%
Other Long-Term Liabilities $44.00K $184.0K $400.0K
YoY Change -89.0% -63.2% -20.0%
Total Long-Term Liabilities $128.1M $125.9M $63.80M
YoY Change 100.79% 101.17% 45.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.94M $15.72M $13.97M
Total Long-Term Liabilities $128.1M $125.9M $63.80M
Total Liabilities $141.3M $141.9M $77.98M
YoY Change 81.22% 93.37% 45.03%
SHAREHOLDERS EQUITY
Retained Earnings -$316.1M -$299.3M -$235.6M
YoY Change 34.19% 38.89% 46.0%
Common Stock $258.1M $256.1M $241.7M
YoY Change 6.8% 6.69% 4.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$58.00M -$43.17M $6.118M
YoY Change
Total Liabilities & Shareholders Equity $83.31M $98.77M $84.10M
YoY Change -0.94% 0.7% -31.84%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$16.81M -$22.63M -$20.07M
YoY Change -16.26% 32.49% 20.4%
Depreciation, Depletion And Amortization $464.0K $106.0K $100.0K
YoY Change 364.0% 17.78% 25.0%
Cash From Operating Activities -$17.45M -$18.40M -$16.45M
YoY Change 6.05% 20.37% 7.73%
INVESTING ACTIVITIES
Capital Expenditures -$53.00K -$25.00K -$50.00K
YoY Change 6.0% -16.67%
Acquisitions
YoY Change
Other Investing Activities $19.70M -$43.02M $16.90M
YoY Change 16.59% -398.51% -140.51%
Cash From Investing Activities $19.65M -$43.04M $16.86M
YoY Change 16.55% -398.69% -140.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.00K 40.61M 240.0K
YoY Change -90.83% 18360.0% -99.6%
NET CHANGE
Cash From Operating Activities -17.45M -18.40M -16.45M
Cash From Investing Activities 19.65M -43.04M 16.86M
Cash From Financing Activities 22.00K 40.61M 240.0K
Net Change In Cash 2.227M -20.83M 650.0K
YoY Change 242.62% 3056.52% -75.29%
FREE CASH FLOW
Cash From Operating Activities -$17.45M -$18.40M -$16.45M
Capital Expenditures -$53.00K -$25.00K -$50.00K
Free Cash Flow -$17.39M -$18.38M -$16.40M
YoY Change 6.05% 20.2% 7.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001563577
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
610
dei Entity File Number
EntityFileNumber
001-39114
dei Entity Registrant Name
EntityRegistrantName
Galera Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1454898
dei Entity Address Address Line1
EntityAddressAddressLine1
2 W. Liberty Blvd #100
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26438767
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17632000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15872000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
71073000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
56904000
dei Local Phone Number
LocalPhoneNumber
725-1500
dei Security12b Title
Security12bTitle
Common Stock,$0.001 par value per share
dei Trading Symbol
TradingSymbol
GRTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3983000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5153000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
92688000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
77929000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
938000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1023000
CY2021Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2021Q3 us-gaap Goodwill
Goodwill
881000
CY2020Q4 us-gaap Goodwill
Goodwill
881000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
374000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
530000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1626000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1477000
CY2021Q3 us-gaap Assets
Assets
98765000
CY2020Q4 us-gaap Assets
Assets
84098000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7181000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5146000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8272000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8584000
CY2021Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
271000
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
238000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15724000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13968000
CY2021Q3 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
125751000
CY2020Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
63369000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
110000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
296000
CY2021Q3 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
273000
CY2020Q4 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
273000
CY2021Q3 us-gaap Other Liabilities
OtherLiabilities
74000
CY2020Q4 us-gaap Other Liabilities
OtherLiabilities
74000
CY2021Q3 us-gaap Liabilities
Liabilities
141932000
CY2020Q4 us-gaap Liabilities
Liabilities
77980000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Interest Expense
InterestExpense
3625000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24976142
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24976142
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
26000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26438767
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26438767
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
256104000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
241649000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
12000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-299295000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-235568000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-43167000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
6118000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98765000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84098000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14813000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12133000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43203000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40225000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5487000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3945000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15667000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11384000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20300000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16078000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58870000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51609000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
235000
us-gaap Investment Income Interest
InvestmentIncomeInterest
28000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1055000
CY2021Q3 us-gaap Interest Expense
InterestExpense
2327000
CY2020Q3 us-gaap Interest Expense
InterestExpense
1235000
us-gaap Interest Expense
InterestExpense
4882000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-193000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
85000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22631000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17271000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
27000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22626000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-17078000
us-gaap Net Income Loss
NetIncomeLoss
-63727000
us-gaap Net Income Loss
NetIncomeLoss
-54152000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.18
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26304920
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24874805
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25569545
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24840822
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22626000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-17078000
us-gaap Net Income Loss
NetIncomeLoss
-63727000
us-gaap Net Income Loss
NetIncomeLoss
-54152000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63741000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54067000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
6118000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1791000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
235000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18715000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-10573000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1611000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
120000
CY2021Q2 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
-5718000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22386000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-25517000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1870000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
890000
CY2021Q3 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
-2221000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22626000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-43167000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
69608000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1210000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
648000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-18417000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
53058000
CY2020Q2 grtx Issuance Of Common Stock Warrants
IssuanceOfCommonStockWarrants
4712000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1453000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
41000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-370000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18657000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
40237000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1505000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
224000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-193000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-17078000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
24695000
us-gaap Profit Loss
ProfitLoss
-63727000
us-gaap Profit Loss
ProfitLoss
-54152000
us-gaap Depreciation
Depreciation
314000
us-gaap Depreciation
Depreciation
272000
us-gaap Paid In Kind Interest
PaidInKindInterest
4882000
us-gaap Paid In Kind Interest
PaidInKindInterest
3625000
us-gaap Share Based Compensation
ShareBasedCompensation
5272000
us-gaap Share Based Compensation
ShareBasedCompensation
4168000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1171000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2089000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-7000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-212000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2035000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
68000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-466000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
631000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50512000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43087000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
67183000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
53650000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
53000000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
73750000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
230000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
411000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14413000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19689000
grtx Proceeds From Royalty Purchase Agreement
ProceedsFromRoyaltyPurchaseAgreement
57500000
grtx Proceeds From Royalty Purchase Agreement
ProceedsFromRoyaltyPurchaseAgreement
20000000
grtx Proceeds From Open Market Sale Agreement
ProceedsFromOpenMarketSaleAgreement
7939000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1246000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
274000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66685000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20274000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1760000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3124000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15872000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18356000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17632000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15232000
grtx Issuance Of Warrants In Conjunction With Amendment To The Royalty Purchase Agreement
IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement
4712000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-11-19
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-299300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
grtx Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5333390
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5026128
grtx Covid Nineteen Update Policy Textblock
CovidNineteenUpdatePolicyTextblock
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19 update</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for some of the Company’s clinical trials. In April 2020, the Company delayed the initiation of the Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, or EUSOM trial, due to concerns with patient enrollment. The first patient was dosed in this trial in June 2020, and target enrollment was decreased to approximately 35 patients due to the delay. This trial was expected to contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients to ensure the Company was positioned to maintain the overall planned size of the safety database in a timely manner. The Company reported topline data from the ROMAN trial in October 2021 and expects to report topline data from the EUSOM trial in the fourth quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company initiated a pilot Phase 2 clinical trial of avasopasem to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19. The trial aimed to enroll up to 50 hospitalized adult patients critically ill with COVID-19 at several sites across the U.S. On June 16, 2021, the Company ceased enrolling subjects in this trial. Enrollment in the trial was limited at the three centers that participated. Due to the overall decline in COVID-related hospitalizations in the U.S. at the time, the Company determined that it was not feasible to complete the trial.</span></p>
us-gaap Fair Value Liabilities Measured On Recurring Basis Debt Instrument Valuation Techniques Change In Technique Quantification Of Effect
FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
0
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2061000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1832000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1123000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
809000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
938000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1023000
us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
300000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1984000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2632000
CY2021Q3 grtx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5986000
CY2020Q4 grtx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5525000
CY2021Q3 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
302000
CY2020Q4 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
427000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8272000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8584000
CY2021Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P6Y
CY2021Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
4700000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
374000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
530000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
271000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
238000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
110000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
296000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
381000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
534000
us-gaap Operating Lease Cost
OperatingLeaseCost
252000
CY2021Q3 grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
5000
CY2020Q3 grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
8000
grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
18000
grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
27000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
81000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
84000
us-gaap Operating Lease Cost
OperatingLeaseCost
243000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
76000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
76000
us-gaap Operating Lease Expense
OperatingLeaseExpense
225000
us-gaap Operating Lease Expense
OperatingLeaseExpense
225000
us-gaap Operating Lease Payments
OperatingLeasePayments
245000
us-gaap Operating Lease Payments
OperatingLeasePayments
344000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
70000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
83000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
266000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
44000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
393000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2599164
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
381000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4782729
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4782729
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.59
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1870000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1505000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5272000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4168000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4463078
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1318852
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.07
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
571257
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
427944
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.40
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
17600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8400000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.904
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.893
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0069
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0126
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0

Files In Submission

Name View Source Status
0000950170-21-003917-index-headers.html Edgar Link pending
0000950170-21-003917-index.html Edgar Link pending
0000950170-21-003917.txt Edgar Link pending
0000950170-21-003917-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
grtx-20210930.htm Edgar Link pending
grtx-20210930.xsd Edgar Link pending
grtx-20210930_cal.xml Edgar Link unprocessable
grtx-20210930_def.xml Edgar Link unprocessable
grtx-20210930_htm.xml Edgar Link completed
grtx-20210930_lab.xml Edgar Link unprocessable
grtx-20210930_pre.xml Edgar Link unprocessable
grtx-ex10_2.htm Edgar Link pending
grtx-ex10_3.htm Edgar Link pending
grtx-ex31_1.htm Edgar Link pending
grtx-ex31_2.htm Edgar Link pending
grtx-ex32_1.htm Edgar Link pending
grtx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending